๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

PMC61 MONITORING OF HEALTH ECONOMIC DATA IN CLINICAL TRIALS

โœ Scribed by M Bharmal; S Viswanathan; E Gemmen

Book ID
118614538
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
74 KB
Volume
13
Category
Article
ISSN
1098-3015

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Current controversies in data monitoring
Current controversies in data monitoring for clinical trials
โœ Pocock, S. J ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› SAGE Publications ๐ŸŒ English โš– 502 KB

This article presents some real-life challenges faced by clinical trial Data Monitoring Committees (DMCs), with the aim of clarifying some of the controversial issues that relate to both statistical stopping boundaries and DMC decision-making. Specific attention is given to what constitutes a sensib

TUTORIAL IN BIOSTATISTICS: BAYESIAN DATA
TUTORIAL IN BIOSTATISTICS: BAYESIAN DATA MONITORING IN CLINICAL TRIALS
โœ PETER M. FAYERS; DEBORAH ASHBY; MAHESH K. B. PARMAR ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 293 KB ๐Ÿ‘ 2 views

Many clinical trials organizations use regular interim analyses to monitor the accruing results in large clinical trials. In disease areas such as cancer, where survival is usually a major outcome variable, ethical considerations may lead to a stipulated requirement for data monitoring of mortality.

Data Monitoring Committees in Clinical T
Data Monitoring Committees in Clinical Trials: A Practical Perspective
โœ Susan S. Ellenberg, Thomas R. Fleming, David L. DeMets ๐Ÿ“‚ Library ๐Ÿ“… 2002 ๐Ÿ› Wiley ๐ŸŒ English โš– 803 KB

There has been substantial growth in the use of data monitoring committees in recent years, by both government agencies and the pharmaceutical industry. This growth has been brought about by increasing recognition of the value of such committees in safeguarding trial participants as well as protecti